T HE HUMAN PLACENTA is a highly invasive structure in which certain trophoblast cells known as the extravillous trophoblast (EVT) arise by proliferation and differentiation of cytotrophoblast stem cells within the chorionic villi, and migrate as cell columns to invade the uterine endometrium and blood vessels to establish an efficient exchange of nutrients and other molecules between the maternal and fetal blood (1, 2). Inadequate EVT cell invasion associated with poor uterine arterial remodeling results in poor placental perfusion, which is regarded as the root cause of preeclampsia and certain forms of intrauterine growth restriction of the fetus (3, 4). On the other hand, hyperinvasiveness of trophoblast is a feature of certain trophoblastic neoplasias, including choriocarcinomas (5).
T HE HUMAN PLACENTA is a highly invasive structure in which certain trophoblast cells known as the extravillous trophoblast (EVT) arise by proliferation and differentiation of cytotrophoblast stem cells within the chorionic villi, and migrate as cell columns to invade the uterine endometrium and blood vessels to establish an efficient exchange of nutrients and other molecules between the maternal and fetal blood (1, 2) . Inadequate EVT cell invasion associated with poor uterine arterial remodeling results in poor placental perfusion, which is regarded as the root cause of preeclampsia and certain forms of intrauterine growth restriction of the fetus (3, 4) . On the other hand, hyperinvasiveness of trophoblast is a feature of certain trophoblastic neoplasias, including choriocarcinomas (5) .
Although many of the molecular mechanisms responsible for EVT cell invasiveness are similar to those of cancer cells (6) , in contrast to cancer cells, their proliferative, migratory, and invasive functions are stringently regulated in situ in a spatiotemporal manner (1, 4, 7) . These EVT cell functions are positively or negatively regulated by a variety of factors produced at the fetomaternal interface, including growth factors, growth factor-binding proteins, extracellular matrix (ECM) components, lipid derived molecules such as prostaglandin estradiol, and proteoglycans (4, 8) , to maintain a normal uteroplacental homeostasis. These factors are produced either by the trophoblast (autocrine) or by cells in the decidua (paracrine) influencing EVT cell functions via their respective receptors expressed by EVT cells.
Although a multitude of factors are known to stimulate proliferative, migratory/invasive functions in an autocrine or paracrine manner (4, 8) , only a limited number of uterusderived molecules (paracrine) have so far been shown to inhibit these functions (8) . For example, migration of EVT cells into the myometrium was inhibited by interaction of Mel-CAM expressed by the EVT with Mel-CAM ligand expressed by uterine smooth muscle cells (9) . TNF-␣, possibly a product of decidual macrophages, inhibits EVT cell invasiveness by up-regulating plasminogen activator inhibitor (PAI)-1 (10) . Two decidua-derived molecules, TGF␤ (11) as well as a TGF␤-binding proteoglycan decorin (DCN) (12) , have been shown to be the key negative regulators of all EVT cell functions, viz. proliferation, migration, and invasiveness.
EVT cells express all the TGF␤ receptors (I, II, and III) as well as downstream signaling molecules, e.g. Smad 2, 3 (13), responsible for the inhibitory signals. Antiproliferative action of TGF␤ on EVT cells (14) is identical to that on most other epithelial cells. Antiinvasive action of TGF␤ on EVT cells (7, 11) results from an up-regulation of tissue inhibitor of metalloproteinase-1 (11) and PAI-1 (15) , as well as down-regulation of urokinase-type plasminogen activator (uPA) (11, 15) . Antimigratory action appears to be due to an up-regulation of integrins, making the cells more adhesive to the ECM (16) .
DCN, a TGF␤-binding proteoglycan made by mesenchymal cells, including the decidua (17) , and colocalized with TGF␤ in the decidual ECM (18) , was shown to exert antiproliferative, antimigratory, and antiinvasive effects on EVT cells independent of TGF␤ (12) . It was suggested that DCN serves as a storage device for TGF␤ in an inactive state, until it is cleaved by plasmin, activated by trophoblast-derived uPA at the invasive front, thus providing a negative signal to limit invasion (12) .
DCN is a prototypical member of the small leucine-rich proteoglycans family, consisting of a globular protein core and a single chondroitin/dermatan sulfate glycosaminoglycan (GAG) chain, located in mesenchymally derived tissues, e.g. dermis and cartilage (19) . This molecule was reported to influence some key biological processes: formation and organization of collagen fibrils in assembly of the ECM (19, 20) ; tissue differentiation; and organogenesis (21) . DCN can modulate numerous cellular functions. It can alter cell adhesion by binding with ECM molecules fibronectin (FN) (22, 23) or thrombospondin (24) . It was reported to have an antimigratory action on endothelial cells (25, 26) and was also shown to impede migration-promoting effects of several matrix molecules, e.g. FN and collagen I (for which it has binding sites) on an osteosarcoma cell line, requiring the presence of the GAG chain (27) . Furthermore, it was shown to have an inhibitory role in proliferation in a number of cell types (28 -30) and also in tumor growth (28, (31) (32) (33) .
DCN can bind TGF␤ through a binding site located in the core protein (34) and in certain cases also inactivate mature TGF␤ (35) . DCN has been antiangiogenic (25, 26, 36) . Purified GAG-free DCN and its 26-residue leucine-rich repeat LRR5 can inhibit vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and serum-induced angiogenesis in endothelial cells in vitro (37) , these functions being ascribed to the DCN core protein.
Despite multiple biological actions of DCN on a variety of cell types, the nature of the cell surface receptors responsible for DCN action has remained elusive in many cases. DCN was shown to interact with epidermal growth factor receptor (EGFR) in a squamous cell carcinoma line, leading to dimerization and autophosphorylation of the receptor, triggering a signal cascade, e.g. activation of MAPKs, mobilization of intracellular calcium, eventual up-regulation of p21, and finally growth suppression associated with a retardation of EGFR recycling to the cell surface (38 -42) . DCN can also interact with IGF receptor (IGFR)-I in endothelial cells, leading to its phosphorylation, followed by a down-regulation of the receptor, resulting in cell survival (43) .
We had earlier shown that antiproliferative effects of DCN on EVT cells were associated with up-regulation of p21 protein, a cell cycle inhibitory molecule (12) . However, the receptors responsible for DCN-mediated inhibition of proliferation and migration of EVT cells remained unknown. The present study was designed with a well-established first-trimester human EVT cell line, HTR-8/SVneo, and in certain experiments with first-trimester human chorionic villus explants in culture to identify mechanisms of DCN action on EVT cells. In view of the fact that DCN can interact with EGFR (39) and IGFR-I (43) and that EVT cells are epithelial cells, which assume an endothelial phenotype in vivo to invade decidualized uterus and its vasculature, we evaluated the possible roles of EGFR, IGFR-I, and VEGF receptor (VEGFR) in DCN inhibitory actions on EVT cells. 
Materials and Methods Reagents

EVT cell line and culture
We used an EVT cell line, HTR-8/SVneo (44) (henceforth, interchangeably called EVT cells), produced in our laboratory by simian virus (SV) 40 tag immortalization of a short-lived first-trimester primary EVT cell line HTR-8, produced by propagation of EVT cells migrating out of a first-trimester chorionic villus explant (45) . HTR-8/SVneo cells, like the primary parental line, express all the markers of EVT in situ, including cytokeratin 7, 8, and 18, placental-type alkaline phosphatase, high-affinity uPA receptor, human leukocyte antigen (HLA) framework antigen w6/32, IGF-II mRNA and protein, and a selective integrin repertoire ␣1, ␣3, ␣5, ␣ v , ␤1, and the vitronectin receptor ␣ v ␤ 3 /␤ 5 (46 -48) . These cells also express HLA-G mRNA and protein when grown on Matrigel (BD Biosciences, San Jose, CA) or laminin (49) , and exhibit phenotypical behavior of freshly isolated cytotrophoblast cells during Matrigel invasion, including the expression of HLA-G (50). Like primary HTR-8 cells, they respond to the migration-stimulating signals of IGF binding protein-1 (47), IGF-II (46) , and uPA (51), as well as to the migration-inhibitory ligands TGB␤ (16) and DCN (12) . Cells at 92-105 passages (100% positive for the EVT cell marker cytokeratin 7) were grown in RPMI 1640 complete medium, including 10% fetal bovine serum, 50 U/ml penicillin, and unless otherwise specified.
Migration assay
Migration (chemokinesis) of HTR-8/SVneo cells was measured as reported earlier (46 -48) , using 24-well Falcon notched plates and cell culture inserts with microporous polycarbonate membrane (8.0-m pore and 6.5-mm diameter; BD, Franklin Lakes, NJ). Briefly, the bottom surface of the membranes was treated, when required, with FN, by exposing each membrane for 90 min at 37 C to a FN solution (75 l at a concentration of 0.01 g/l in 10 mm Tris-HCl buffer); membranes were then dried inside the laminar flow hood, and subsequently soaked in RPMI 1640 containing 3% BSA (for 60 -90 min) to block nonspecific binding sites, and were finally washed twice in Hanks' Balanced Salt Solution. Desired cell concentrations used for the migration assays in the absence of DCN or after a brief exposure to DCN for 30 min at 4 C or 37 C are detailed in Results. In some experiments, as explained in the Results, DCN treatment at 4 C was preceded by the treatment of cells with a tyrosine kinase receptor (TKR) inhibitor (PPP at 500 nm, CPCA at 500 nm, AG1478 at 2 m, and KRN633 at 300 nm, respectively) for 30 min at 4 C. To remove treatment agents, cells were finally washed twice in serumfree medium with 0.2% BSA (SFM) and then resuspended in the same solution, before plating. Two hundred microliters of treated cells (1.5 ϫ 10 5 cells per ml) were placed in the upper chamber (insert), whereas the lower chamber (well) was filled with 800 l SFM. The migration device was incubated for 6 -48 h in a 37 C, 5% CO 2 . After the desired period of time, the upper surface of the membranes was wiped gently with cotton swabs to remove nonmigratory cells. Then the membranes were stained with Harleco Hematocolor staining kit (EM Science, Gibbstown, NJ), and the absolute number of migrant cells was scored visually using light microscope at ϫ400 magnification (two independent researchers blind to experimental conditions). Each condition was tested in triplicate, and experiments were repeated at least three times. Migration data were presented as the mean of absolute values.
Cellularity assay
Cellularity was measured with the WST-1 kit as per manufacturer's protocol. In brief, cells were harvested with 0.05% trypsin-EDTA and resuspended in serum-reduced (RPMI 1640 plus 1% fetal bovine serum) medium (SRM). Cells treated similarly as the migration assay were cultured in 96-well plates (2.5 ϫ 10 5 cells per ml, 100 l/well) for 48 h at 37 C before the addition of 10 l WST-1/well, followed by another 2.5 h incubation. Absorbance of formazan was measured at 450 nm. Cellularity deduced from the absorbance data using the linear part of standard absorbance curves produced with predetermined cell numbers was presented as percentage of controls.
Proliferation assay
The effect of various receptor inhibitors and DCN treatments on proliferation of HTR-8/SVneo cells was assessed using a colorimetric immunoassay based on the measurement of BrdU (pyrimidine analog) incorporation during DNA synthesis in proliferating cells using the cell proliferation ELISA, BrdU colorimetric kit from Sigma according to the manufacturer's instructions. Cell were prepared and treated as described previously for the cellularity assay. The data were presented as the percentage of controls.
Chorionic villus explant culture
We measured the outgrowth of EVT cells in situ as reported earlier (48, 52) . In brief, placentae at 7-9 wk elective pregnancy terminations were collected (in accordance with the institutional ethics review and approval guidelines set by the Department of Obstetrics and Gynecology, University of Western Ontario), and then carefully dissected to remove fetal membranes and endometrial tissue, and to obtain villus fragments. For plating these fragments, we used Millicell-CM culture dish inserts (Millipore, Bedford, MA), which were coated with 200 l 1:6 dilution of Growth Factor Reduced Matrigel (Collaborative Biomedical Products, Bedford, MA). The inserts were incubated at 37 C for 30 min to allow polymerization of the Matrigel, and then were placed in 24-well plates (BD) containing 800 l of the serum-free DMEM/F12 medium (Life Technologies Inc., Grand Island, NY) supplemented with 50 U/ml penicillin, 50 g/ml streptomycin, and 0.25 mg/ml ascorbic acid (Sigma) (pH 7.4), with or without various treatments. The chorionic villi were plated in the prepared inserts as small fragments of villus tips (10 -15 mg wet weight). To assess the viability of the villus fragments, culture media were changed every 48 h, and human chorionic gonadotropin and progesterone concentrations were measured using RIA (Coat-A-Count; Diagnostic Products Corp., Los Angeles, CA). The identity of EVT cells in the outgrowths was confirmed with immunostaining for cytokeratin-7. For each experiment at least three placentae were used, and explants were tested in triplicates for each experimental condition. Pictures of the villus explants were taken every 24 h, up to 72 h using an inverted light microscope (ϫ40 objective). The area of EVT cell outgrowth in cultures was measured using Scion Image for Windows software (version ␤ 4.0.2; Scion Corp., Frederick, MD).
Immunoblotting of phosphorylated IGFR-I and VEGFR-2
HTR-8/SVneo cells were grown on poly-l-lysine-coated dishes and serum starved for 24 h (for phospho-IGF-R1) or 48 h (for phospho-VEGF-R2). Cells were then treated for 0, 3, 5, 10, or 15 min with 10 nm DCN (with or without pretreatment for 30 min with 500 nm PPP and 300 nm KRN633, respectively), or for 5 min with 100 ng/ml IGF-I, and 10 ng/ml VEGF 121 , respectively. The cells were lysed in RIPA buffer containing phosphatase inhibitors (50 mm NaF and 1 mm Na 3 VO 4 ) and protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany) for 0.5 h at 4 C. The protein samples (20 g/lane) were analyzed by SDS-PAGE before transfer to nitrocellulose membranes. Membranes were incubated with antiphospho-antibodies to IGFR-I (1:500 dilution) or VEGFR-2 (1:500), followed by horseradish peroxidaseconjugated secondary antibodies (1:10,000), and developed with ECL Plus Western Blotting Detection System (Amersham Pharmacia, Oakville, Ontario, Canada). ␤-Actin was used as a loading control.
Statistical analysis
Data on migration, cell viability, proliferation, and invasiveness were assessed using two-way ANOVA, followed by normalization of the values as a percentage of the control. Differences among treatment means were analyzed by the Student's t test. All the values were expressed as the mean Ϯ sd. Differences were accepted as significant at P Ͻ 0.05.
Results
DCN inhibits EVT cell outgrowth in situ, in a TGF␤-independent manner
To validate the inhibitory effects exerted by DCN on EVT cells in situ, we investigated EVT cell outgrowth (a combined effect of proliferative and migratory abilities) from villus explants on growth factor-reduced Matrigel. Effects of exogenous DCN at various concentrations (50 -200 nm) were evaluated on the centrifugal spreading of EVT cells (confirmed by the labeling of cytokeratin 7, not shown here) from preformed columns at the point of plating.
As seen in Fig. 1A , untreated explants displayed a minor degree of sprouting/spreading (shown with arrows) under these conditions at time points starting at 24 h, whereas DCN-treated explants exhibited nearly no spreading. When explants were exposed to a TGF␤-neutralizing antibody, the degree of EVT cell spreading (as measured by the area covered by the migrant cells on the surface of Matrigel) increased progressively up to 72 h, evidently due to a release from the inhibitory effects of endogenous TGF␤. TGF␤ has been a key inhibitor of EVT cell proliferation (14) , migration (16, 47) , and invasion (7, 11) .
DCN was shown to bind and inactivate TGF␤ under certain conditions (34, 35) . To assess DCN action independent of endogenous TGF␤, subsequent experiments were done under a combined treatment (CT) of TGF␤ antibody (T-ab) and DCN. Compared with T-ab treated explants, addition of DCN in combination with T-ab caused a suppression of the outgrowth in a DCN concentration-dependent manner at all time points. These results suggest that DCN exerts a TGF␤-independent inhibitory effect on EVT cell outgrowth in situ from intact chorionic villi, in concordance with the earlier reported data with primary EVT cells in culture (12) . For all conditions presented, cell spreading is indicated by arrows, quantified (Fig. 1B) , and presented as an index (ratio of exp/control) of the outgrowth area.
DCN effect on EVT cells migration on FN substrate
Previously, we had demonstrated migration-inhibitory action of DCN on EVT cells in the presence of serum-reduced medium (12) . To exclude possible unknown effects of serum factors, current migration assays were conducted in serumfree medium (48) , but in association with FN-undercoating of the membranes. We had previously shown that EVT cells produce FN (45) and use it as their natural substrate for adhesive and locomotor functions. Indeed, access to FN receptor (␣ 5 /␤ 1 integrin) is essential for EVT cell migration (16) . Because production of native FN by the EVT cell line requires a time lag, the use of FN-undercoated membranes was an expeditious way to improve migration and to increase the sensitivity of the assays to study the inhibitory role of DCN. FN was used at an optimal concentration of 0.01 g/l, decided on the basis of preliminary experiments (data not shown).
To identify the influence of FN coating, the microporous polycarbonate membranes of the migration chambers were used with or without FN undercoating. As noted in Fig. 2A , in SFM, without FN undercoating, very few cells migrated at any of the time points tested with the seeded number of cells. There was a robust improvement of cell migratory ability on FN-coated membranes, in a time-dependent manner. Because the migration reached a near plateau between 24 and 48 h, the 24-h time point was used for all subsequent experiments to determine the influence of DCN. On the basis of preliminary experiments (results not shown), we chose an optimal concentration of HTR-8/SVneo cells at 1.5 ϫ 10 5 cells per ml, allowing us to count all the migrant cells appearing on the undersurface of whole membrane.
Because DCN core protein has binding sites for FN (34) and may inhibit cell adherence by interacting with heparinbinding and cell-binding domains of FN (23, 53) , we first tested the effects of DCN (at 0, 10, 50, and 100 nm in SFM) on EVT cell adhesion in FN-coated wells at 30, 60, and 90 min. Cell adhesion assay, in which cells were quantified by WST-1 colorimetric method (data not shown), revealed no influence of DCN on EVT cell adhesion on FN-coated wells.
We hypothesized that DCN can impede EVT cell locomotion on FN-undercoated membranes, by a direct binding of DCN protein to a potential cell membrane component (a putative receptor). As a preliminary test of this hypothesis, we compared the migratory ability of cells after a 30-min exposure to various concentrations of DCN at 37 vs. 4 C. In both cases the cells were washed to remove the excess of DCN and, subsequently, subjected to the typical migration assay at 37 C. We reasoned that a retardation of both cell membrane fluidity and dissociation of the ligand-receptor complex at 4 C (54) may enhance receptor-mediated DCN action on cell migration, whereas treatment at the two different temperatures should make no difference, if the effects are mediated by DCN binding to the FN substrate alone.
As shown in Fig. 2B , brief DCN treatment at 37 C caused a DCN concentration-dependent inhibition of migration, especially at 10 and 50 nm. However, the inhibitory effects were more pronounced at all DCN concentrations when the DCN exposure was at 4 C. This experiment was repeated four times, with consistency. It should be pointed out that there was no difference in EVT cell migration in the absence of DCN (controls) at 4 vs. 37 C, showing that cooling of the cells alone during the initial period did not influence their subsequent migratory ability. Because treating cells with DCN at 4 C increased the sensitivity of the assay, this temperature for initial treatments was used in further migration experiments to test the role of cell surface receptors. DCN concentrations were kept at 10 and 50 nm, which were shown to be inhibitory.
Effects of TKR inhibitors and DCN in EVT cell migration
We had earlier shown that our EVT cell line expresses functional EGFR (55, 56) , IGFR-I (57), and VEGFR-2 (58). To test if blocking any of these TKRs mitigates migration-inhibitory action of DCN, we exposed cells to TKR-specific inhibitors and then to DCN (10 and 50 nm), both at 4 C for 30 min, followed by washing. EVT cells were allowed to migrate for 24 h at 37 C. IGFR-I was reported to mediate DCN action on endothelial cells (43) . To test if IGFR-I participates in mediating migration inhibitory effect of DCN on EVT cells, we used a specific IGFR-I inhibitor, PPP, at 500 nm, shown earlier to block this receptor efficiently without any toxic effect (59) . Results presented in Fig. 3A show no significant difference in cell migration between the untreated (control) and PPP-treated cells, suggesting that the IGFR-I inhibitor itself does not exert a significant inhibition of EVT cell migration. DCN alone at both 10 and 50 nm exerted the expected inhibition. Combining PPP followed by DCN, the inhibitory action of DCN was significantly (P Ͻ 0.05) diminished, compared with PPP-treated cells. This restitution of EVT cell migration suggests that inhibitory action of DCN was impaired by PPP, implicating a possible role of IGFR-I in DCN inhibitory action.
It has been shown that DCN can bind EGFR (39, 41) to mediate growth inhibitory actions on certain carcinoma cells (40) . To evaluate the role of EGFR in migration-inhibitory action of DCN on EVT cells, we tested the effects of two different EGFR-specific inhibitors: CPCA at a noncytotoxic concentration of 500 nm (results not shown); and tyrphostin AG1478 at a concentration of 2 m, reported previously to block effectively the activation of the EGFR kinase (38) and shown to be nontoxic in the present assays. Fig. 3B shows that neither CPCA nor AG1478 alone has any significant effect on EVT cell migration on the FN substrate. On the other hand, DCN alone significantly inhibited migration at both DCN concentrations, as expected. When DCN was added after pretreatments with EGFR inhibitors, the migratory ability of the cells was not affected significantly. This lack of restoration indicates that migration impairment with DCN was not likely mediated by EGFR.
The possible role of VEGFRs in DCN action has never been tested. However, it was reported that DCN or certain DCN peptides can inhibit VEGF-mediated endothelial tube formation in vitro (37) and that DCN is able to suppress tumor cell-mediated angiogenesis (36) . In view of these reports, we examined the role of VEGFR in DCN inhibition of EVT cell functions. Cells were pretreated with an inhibitor of VEGFRs (R1, R2, and R3), KRN633, at an optimal nontoxic (results not shown) concentration of 300 nm. Figure 3C shows that KRN633 alone does not have a significant effect on EVT cell migration, as compared with untreated cells, whereas, as expected, DCN alone at both concentrations inhibited migration. Pretreatment of cells with KRN633, followed by DCN treatment, showed no significant alteration in the inhibitory effects of DCN at either DCN concentration, as compared with DCN treatment alone. An absence of migrationrestituting ability of the VEGFR inhibitor suggested that any of the VEGFRs is not involved in DCN-mediated inhibition of EVT cell migration. Figure 4 presenting the results of WST-1 assay shows that EVT cell proliferation/survival is not influenced by PPP, CPCA/AG1478, or KRN633 alone compared with the untreated cells. DCN at 10 and 50 nm exerted a significant dose-dependent inhibition as reported earlier (12) . When cells were pretreated with 500 nm PPP (Fig. 4A ), no effect on cellularity was noticed compared with corresponding DCN only treated cells. In contrast, as noted in Fig. 4B , inhibition of EGFR with CPCA (500 nm) or AG1484 (2 m), followed by DCN treatment resulted in a significant restoration of cellularity to above the level of DCN alone-treated cells and comparable to the level of inhibitor-treated cells. A significant restorative effect was also noticed in EVT cell cellularity by VEGFR inhibitor (KRN633) pretreatment before DCN addition, as shown in Fig. 4C . These results suggest the roles of EGFR and VEGFR, but not IGFR-I, in DCN-mediated reduction of EVT cell cellularity.
Roles of TKRs in the cellularity of DCN-treated EVT cells
Role of TKRs in the proliferative ability of DCN-treated cells
To test whether the results obtained with the cellularity assays were a consequence of DCN effects on proliferative ability, we quantified BrdU incorporation into DNA.
As presented in Fig. 5 , treatments of HTR-8/SVneo cells with IGFR-I inhibitor, EGFR inhibitors, or VEGFR inhibitor alone had no significant effect on their proliferative ability. These results are consistent with the absence of endogenous proliferation-stimulating ligands to any of these receptors expressed by EVT cells. DCN alone at 10 and 50 nm resulted in a pronounced and concentration-dependent antiproliferative effect, as reported earlier (12) . As noted in Fig. 5A , PPP treatment before DCN did not significantly alter antiproliferative effects of DCN, suggesting that IGFR-I is not involved. In contrast, Fig. 5B shows a restoration of proliferation of cells treated with either CPCA or AG1478 before DCN treatment at the respective concentrations, revealing that DCN inhibition of EVT cell proliferation might be mediated by EGFR. Similarly, antiproliferative effects of DCN were significantly mitigated by pretreatment with KRN633 (Fig. 5C ), suggesting participation of one or more of the VEGFRs.
All of the aforementioned experiments were repeated at least three times with consistency.
DCN effect on IGFR-I and VEGFR-2 phosphorylation
Because EGFR has been the most well-studied receptor identified for antiproliferative actions of DCN on other cells (38 -41) , our functional studies implicating this receptor in antiproliferative action of DCN on EVT cells was not sur- Fig. 3 ). DCN alone caused significant (P Ͻ 0.01) inhibition in cellularity in all experiments. A significant restoration (P Ͻ 0.01) of cellularity was caused by pretreatment with CPCA, AG1478, or KRN633, but not PPP. Symbols are the same as in Fig. 3 . Figs. 3 and  4) . Although DCN alone caused significant inhibition of proliferation (P Ͻ 0.01), a significant restoration of proliferative ability (P Ͻ 0.05) was caused by pretreatmen with CPCA, AG1478, or KRN633, but not PPP. Symbols are the same as in Fig. 3. prising. However, the role of IGF-IR in DCN action has been reported in a single study (43) , and the role of VEGFRs has never been tested. For these reasons we decided to test whether DCN could stimulate phosphorylation of IGFR-I or VEGFR-2 (the angiogenic receptor for VEGF) on EVT cells and if so, whether the phosphorylation events could be blocked with respective receptor inhibitors.
FIG. 4. Cellularity of EVT (HTR-8/SVneo) cells treated with DCN and different TKR inhibitors (as in
FIG. 5. Proliferation (BrdU incorporation) of EVT (HTR-8/SVneo) cells treated with DCN and different TKR inhibitors (as in
As seen in 
Discussion
We had earlier shown that DCN controls proliferation, migration, and invasiveness of the human trophoblast in a TGF␤-independent manner (12) . By using explants of undisrupted human first-trimester chorionic villi, the present study confirmed DCN action in situ, indicating the physiological role of this molecule at the fetomaternal interface. Because DCN is not produced by the trophoblast of the chorionic villi and is localized to the ECM associated with mesenchymal cells of the villus core (17, 18) , we reasoned that exogenous DCN should exert its action on EVT cell outgrowth in villus explants cultured in serum-free medium. However, DCN has been shown to bind TGF␤ and in some cases, also inactivate TGF␤ (35) . To exclude the confounding effects of endogenous TGF␤ in the system, we treated the explants with a TGF␤ neutralizing antibody to identify DCN effects. As expected, treatment with the antibody alone stimulated EVT cell outgrowth (a combined effect of proliferation and migration), evidently owing to the inactivation of endogenous TGF␤, a known negative regulator, and additional treatment with DCN led to suppression of the outgrowth. It can be suggested that DCN had no TGF␤ inactivating function in situ because one would expect a promotion of the outgrowth at lower DCN concentrations due to further inactivation of any residual TGF␤ that may not have been fully neutralized by the antibody treatment. However, this suggestion remains to be validated further. Finally, our explant system did not distinguish between DCN effects on EVT cell proliferation and migration, which were only distinguishable with distinct assays in our EVT cell culture system. The present study, for the first time, provided an insight into the mechanisms responsible for proliferation and migration-inhibitory effects of DCN on the trophoblast. Migration-inhibitory effects of DCN on FN-undercoated membranes were more pronounced when cells were briefly exposed to DCN at 4 C than at 37 C before the migration assay, suggesting (but not proving) that interaction of DCN with cell membrane constituent(s), rather than the FN substrate, was responsible for the functional effects. This experiment was relevant because DCN has distinct cell binding and FN binding sites (34) , and certain effects of DCN by FN binding have been ascribed to the GAG chain (27) , rather than the protein core, where putative cell binding sites (re- ceptors) exist. In subsequent experiments, by preincubating EVT cells briefly with specific inhibitors of certain TKRs (known to be expressed by the EVT cells) before cell exposure to DCN, we demonstrated that the inhibitors selectively abrogated DCN-mediated inhibitory effects on migration or proliferation, whereas having no effect on their own on the specific EVT cell function tested. These functional data suggested that IGFR-I was responsible for migration-inhibitory action, whereas EGFR as well as VEGFR (most likely VEGFR-2) were responsible for the proliferation-inhibitory effects of DCN on EVT cells. In further experiments we demonstrated DCN-mediated phosphorylation of IGFR-I and VEGFR-2, which also occurred with their natural ligands, and that this phosphorylation could be efficiently blocked with specific receptor inhibitors used in the functional assays. These results, together, revealed that multiple TKRs mediate DCN effects on EVT cells in a function-specific manner, a finding not reported earlier for any other cell type. Furthermore, to our knowledge, the involvement of VEGFR-2 in DCN action is a novel finding, not reported earlier for any cell type.
Previous studies have shown that DCN has multiple binding partners of various molecular sizes on the cell membrane (60) . Of these, two receptors (EGFR and IGFR-I) have been studied in some detail. In both cases, DCN binds the receptors with lower affinity than that of their natural ligands, leading to inhibitory signals, eventually associated with a down-regulation of the receptors on the cell membrane. A series of studies by Iozzo and colleagues (38 -42) demonstrated that: antiproliferative effects of DCN on a squamous carcinoma cell line overexpressing EGFR is mediated by EGFR; DCN causes a phosphorylation of the receptor, followed by endocytosis of the receptor into the caveolar pathway, eventually leading to receptor down-regulation on the cell membrane resulting from retardation of receptor recycling; DCN binding sites on the EGFR overlap partially but not totally with the EGF binding sites; and antiproliferative effects of DCN are associated with up-regulation of certain cell cycle inhibitory proteins such as p21, as reported by us for EVT cells (12) , or p27. We believe that DCN mediated proliferation inhibition of EVT cells owing to interaction with EGFR follows similar events. Involvement of IGFR-I in DCN action has been reported earlier with endothelial cells, in which case, DCN was shown to induce IGFR-I phosphorylation and up-regulation of p21 (43) . The IGFR-I binding region of DCN was mapped to the N terminus of the molecule. No information is available on the molecular nature of the DCN-binding vs. IGF-I binding sites on the IGFR-I. Our findings of the role of IGFR-I as well as VEGFR-2 are interesting in light of the fact that EVT cells assume an endothelial phenotype while invading uterine arteries (61) .
The role of VEGFR (R2) demonstrated for antiproliferative effects of DCN on EVT cells has not been reported earlier for any cell type. It is interesting to note that VEGF-mediated angiogenesis in vitro was reported to be inhibited with DCN and certain DCN peptides, resulting from inhibition of VEGF-induced endothelial cell migration and tube formation (37) . These findings prompted us to examine the possible role of VEGFR-2 in DCN action. We suggest that, similar to our findings on EVT cells, the DCN inhibitory effects on VEGFinduced angiogenesis are likely due inhibitory effects of DCN on endothelial cells via VEGFR-2. Future experiments to compare DCN binding vs. VEGF-A binding regions of VEGFR-2, as well as to identify VEGFR-2 binding sites on the DCN core protein will be important in designing potent inhibitors of angiogenesis. It will also be interesting to test whether DCN peptide fragments identified by the aforementioned authors (37) having stronger antiangiogenic action than that of DCN protein include VEGR-2 binding sites on the DCN.
Although the present studies used natural DCN inclusive of the GAG chains, we believe that the results are due to the binding of the core protein to putative receptors. They remain to be extended at the molecular levels to identify DCN binding proteins on the EVT cell surface, including the presently identified receptors as well as others that may be of functional importance. The present findings are highly relevant to the understanding of molecular aberrations in the pathogenesis of preeclampsia, a trophoblast hypo-invasive disorder that is multifactorial in origin (4). Aberrant angiogenic/vascular responses, including the role of increased soluble VEGFR-1 (Flt-1) leading to the reduction of bioavailable placental growth factor/VEGF at the fetomaternal interface, have been proposed in the genesis of preeclampsia (62) . We hypothesize that either DCN overexpression in the decidua or an aberrant release of certain decidua-derived DCN peptides may play a dual role in the etiology of preeclampsia. For example, those peptides with an increased ability to block VEGF action because of binding to VEGFR-2 may retard angiogenesis or vascular responses by their action on endothelial cells, and those with an increased ability to bind IGFR-I may make trophoblast cells hypo-migratory and hypo-invasive.
We have earlier shown that choriocarcinoma cells are refractory to antiproliferative, antimigratory, and antiinvasive action of DCN (12) . The underlying molecular mechanisms remain to be explored.
